Identification and characterization of a peptide with affinity to head and neck cancer

Journal of Nuclear Medicine

Volumn 50, Issue 3, 2009, Pages 426-434

  Nothelfer, Eva Maria ^a,b   Zitzmann Kolbe, Sabine ^c   Garcia Boy, Regine ^a   Krämer, Susanne ^a   Herold Mende, Christel ^a   Altmann, Annette ^a,b   Eisenhut, Michael ^b   Mier, Walter ^a   Haberkorn, Uwe ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c BAYER PHARMA AG   (Germany)

Author keywords

Integrin v 6Head and neck cancer; Peptides; Phage display; RGD; Tumor targeting

Indexed keywords

ALPHAVBETA6 INTEGRIN; IODINE 125; PEPTIDE DERIVATIVE; PEPTIDE HBP 1 IODINE I 125; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BINDING; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG IDENTIFICATION; FEMALE; FLUORESCENCE; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; SEQUENCE ANALYSIS; TUMOR XENOGRAFT;

AMINO ACID SEQUENCE; ANIMALS; CELL LINE, TUMOR; HEAD AND NECK NEOPLASMS; HUMANS; IODINE RADIOISOTOPES; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR SEQUENCE DATA; NEOPLASM TRANSPLANTATION; OLIGOPEPTIDES; PEPTIDE LIBRARY; RADIOPHARMACEUTICALS;

EID: 62449166018     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.108.058123     Document Type: Article

References (37)

1. Reuter CW, Morgan MA. Eckardt A. Targeting EG F-receptor- signal ling in squamous cell carcinomas of the head and neck. Br J Cancer. 2007;96:408-416.
2. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev. 2003;24:389-427.
3. Matar P. Rojo F, Cassia R, et al. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD J 839) and the monoclonal antibody celuximab (IMC-C225): superiority over single-agent receptor targeting. Clin Cancer Res. 2004;10:6487-6501.
4. Raguse JD, Gath HJ, Bier J, Riess H, Oettle H. Cilengitide (EMD 121974) arrests the growth of a heavily pretrealed highly vascularised head and neck tumour. Oral Oncol 2004;40:228-230.
5. Szardenings M. Phage display of random peptide libraries: applications, limits, and potential. J Recept Signal Transduct Res. 2003;23:307-349.
6. Haberkorn U, Eisenhut M, Altmann A, Mier W. Endoradiolherapy with peptides: status and future development. Curr Med Chem. 2008;15:219-234.
7. Ninck S, Reisser C. Dyckhoff G, Helrnke B, Bauer H. Herold-Mende C. Expression profiles of angiogenic growth factors in squamous cell carcinomas of the head and neck. Int J Cancer. 2003; 106:34-44.
8. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins: identification by morphologic and immunologic criteria. J Clin Invest. 1973;52:2745-2756.
9. Wettings DA, Atherton E. Standard Fmoc protocols. Methods Enzymol. 1997; 289:44-67.
10. Crim JW, Garczynski SF, Brown MR. Approaches to radioiodination of insect neuropeptides. Peptides. 2002;23:2045-2051.
11. Herold-Mende C, Seiter S, Born AI, et al. Expression of CD44 splice variants in squamous epithelia and squamous cell carcinomas of the head and neck. J Pathol. 1996;179:66-73.
12. DiCara D, Rapisarda C. Sutcliffe JL, et al. Structure-function analysis of Arg- Gly-Asp helix motifs in alpha v beta 6 integrin ligands. J Biol Chem. 2007; 282:9657-9665.
13. Elayadi AN. Samli KN. Prudkin L. et al. A peptide selected by biopanning identifies the integrin alphavbeta6 as a prognostic biomarker for nonsmall cell lung cancer. Cancer Res. 2007;67:5889-5895.
14. Weiner RE, Thakur ML. Radiolabeled peptides in oncology: role in diagnosis and treatment. BioDrugs. 2005;19:145-163.
15. Reubi JC. Somatostatin and other peptide receptors as tools for tumor diagnosis and treatment. Neuroendocrinology. 2004;80 (suppl 1):51-56.
16. Wangler C, Buchmann I, Eisenhut M, Haberkorn U. Mier W. Radiolabeled peptides and proteins in cancer therapy. Protein Pept Lett. 2007;14:273-279.
17. Amaout MA, Goodman SL, Xiong JP Structure and mechanics of integrin-based cell adhesion. Curr Opin Cell Biol. 2007;19:495-507.
18. Danen EH. Integrins: regulators of tissue function and cancer progression. Curr Pharm Des. 2005;11:881-891.
19. Mizejewski GJ. Role of integrins in cancer: survey of expression patterns. Proc Soc Exp Biol Med. 1999;22:124-138.
20. Georgolios AK, Batistatou A, Charalabopoulos K. Integrins in head and neck squamous cell carcinoma (HNSCC): a review of the current literature. Cell Common Adhes. 2005;12:1-8.
21. Thomas GJ, Jones J, Speight PM. Integrins and oral cancer. Oral Oncol. 1997:33:381-388.
22. 99mTc-labeled quinolin-4-one peptidomimetics as ligands for the vitronectin receptor: potential tumor imaging agents. Bioconjug Chem. 2006; 17:1294-1313.
23. Tsuchiya Y, Sawada S, Tsukada K, Saiki I. A new pseudo-peplide of Arg-Gly- Asp (RGD) inhibits intrahepatic metastasis of orthotopically implanted murine hepatocellular carcinoma. Int J Oncol. 2002;20:319-324.
24. Swenson S. Costa F, Ernst W, Fujii G. Markland FS. Conlorlrostatin, a snake venom disintegrin with anti-angiogenic and anti-tumor activity. Pathophysiol Haemost Thromb. 2005;34:169-176.
25. Burke PA, DeNardo SI Miers LA, Lamborn KR, Malzku S. DeNardo GL. Cilengilide targeting of alpha(v)bela(3) integrin receptor synergizes with radio immunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res. 2002;62:4263-4272.
26. Hehlgans S, Haase M, Cordes N. Signalling via integrins: implications for cell survival and anticancer strategies. Biochim Biophys Acta. 2007;1775:163-180.
27. Frochot C, Di Stasio B, Vanderesse R, et al. Interest of RGD-containing linear or cyclic peptide targeted tetraphenylchlorin as novel photosensitizers for selective photodynamic activity. Bioorg Chem. 2007;35:205-220.
28. Huang X, Wu J, Zhu W, Pytela R, Sheppard D. Expression of the human integrin beta6 subunit in alveolar type II cells and bronchiolar epithelial cells reverses lung inflammation in beta6 knockout mice. Am J Respir Cell Mol Biol. 1998;19:636-642.
29. 18F-labelled linear peptides. Eur J Nucl Med Mol Imaging. 2002;29:754-759.
30. 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 2001;61:1781-1785.
31. Vasudevan S. Celikel R, Ruggeri ZM, Varughese KI, Kunicki TJ. A single amino acid change in the binding pocket alters specificity of an anli-integrin antibody AP7.4 as revealed by its crystal structure. Blood Cells Mol Dis. 2004;32:176-181.
32. Herold-Mende C. Kartenbeck J. Tomakidi P, Bosch FX. Metastatic growth of squamous cell carcinomas is correlated with upregulation and redistribution of hemidesmosomal components. Cell Ttssue Res. 2001;306:399-408.
33. 18F]galacto-RGD: synthesis, radio- labeling, metabolic stability, and radiation dose estimates. Bioconjug Chem. 2004;15:61-69.
34. Wester HJ, Kessler H. Molecular targeting with peptides or peptide-polymer conjugates: just a question of size? J Nucl Med. 2005;46:1940-1945.
35. Nishikawa N, Komazawa H, Orikasa A, et al. Synthesis and biological properties of partially modified retro and retro-inverso pseudo peptides of Arg-Gty-Asp (RGD). Bioorg Med Chem Lett. 1996;6:2725-2728.
36. 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression. J Nucl Med. 2004;45:1776-1783.
37. Yang W, Meng L, Wang H, et al. Inhibition of proliferative and invasive capacities of breast cancer cells by arginine-glycine-aspartic acid peptide in vitro. Oncol Rep. 2006:15:113-117.